

## CURRICULUM VITAE



### PERSONAL INFORMATION

Name	<b>Alberto Zambon</b>
Address	(Office) Clinica Medica 1, Policlinico - Via Giustiniani 2, 35128 Padova, Italy
Telephone	Phone +39.049.8212150 (Office)
Fax	Fax +39.049.8212151
E-mail	<a href="mailto:alberto.zambon@unipd.it">alberto.zambon@unipd.it</a> or <a href="mailto:iodza@tin.it">iodza@tin.it</a>
Nationality	Italian
Date of birth	December 21 <sup>st</sup> , 1961

### EXPERTISE

- Principal areas of expertise

MD: Internal Medicine, Endocrinology and Metabolism  
PhD: Atherosclerosis, Lipid and lipoprotein metabolism, Lipid-lowering therapy and cardiovascular disease prevention, Atherosclerotic plaque pathophysiology

### WORK EXPERIENCE

- Dates (from – to)
- Name and address of employer
  - Type of business or sector
  - Occupation or position held
- Main activities and responsibilities

PRESENT  
University of Padova, Dept. of Medicine, Via Giustiniani 2, 35128 Padova - Italy  
Physician – Academic teaching Hospital  
ASSOCIATE PROFESSOR OF MEDICINE  
Inpatient clinic: Internal medicine ward; Outpatient: lipid clinic; Tutor for post-doctoral fellows in Endocrinology and Metabolism, Teaching activity: General Medicine and Endocrinology-Metabolism courses for Medical School Students

- Dates (from – to)
- Name and address of employer
  - Type of business or sector
  - Occupation or position held
- Main activities and responsibilities

07/1999 – 06/2000  
Division of Metabolism Endocrinology and Nutrition, University of Washington, 1959 N.E. Pacific St., Seattle, WA, USA  
Physician – Academic teaching Hospital  
ACTING ASSISTANT PROFESSOR OF MEDICINE  
Research on lipid metabolism; Teaching classes: Endo-Metabolism Course, Medical School

- Dates (from – to)
- Name and address of employer
  - Type of business or sector
  - Occupation or position held
- Main activities and responsibilities

07/2000 - PRESENT  
Division of Metabolism Endocrinology and Nutrition, University of Washington, 1959 N.E. Pacific St., Seattle, WA, USA  
Physician – Academic teaching Hospital  
AFFILIATE ASSISTANT PROFESSOR OF MEDICINE  
Research on lipid metabolism and atherosclerosis, and genetic forms of lipid disorders

## EDUCATION AND TRAINING

- Dates (from – to) 01/1982 – 07/1988
  - Name and type of organization providing education and training Medical School – University of Padova, Italy
  - Principal subjects/occupational skills covered Medicine and Surgery
  - Title of qualification awarded Doctor in Medicine - M.D.
  - Level in national classification
- 
- Dates (from – to) 01/1991 – 03/1993 and 07/1995 – 11/1997
  - Name and type of organization providing education and training Division of Endocrinology, Metabolism and Nutrition, School of Medicine, University of Washington, Seattle, WA, USA
  - Principal subjects/occupational skills covered Post doctoral training in Endocrinology and Metabolism – Outpatient Lipid Clinic
  - Title of qualification awarded Fellowship in Endocrinology and Metabolism
  - Level in national classification
- 
- Dates (from – to) 12/1993
  - Name and type of organization providing education and training School of Medicine, University of Padova, Italy
  - Principal subjects/occupational skills covered Clinical Endocrinology and Metabolism
  - Title of qualification awarded National Board Certification in Endocrinology and Metabolism
  - Level in national classification
- 
- Dates (from – to) 06/1998
  - Name and type of organization providing education and training School of Medicine, University of Padova, Italy
  - Principal subjects/occupational skills covered Clinical and basic science research in the pathophysiology of aging and atherothrombotic process
  - Title of qualification awarded Ph.D. in Gerontology
  - Level in national classification
- 
- Dates (from – to) 07/2004 – 08/2004 and 07/2006 – 08/2006
  - Name and type of organization providing education and training Children's Hospital Oakland Research Institute (CHORI), Lipid Laboratory, Oakland, CA, USA
  - Principal subjects/occupational skills covered Lipoprotein metabolism – Advanced techniques to assess lipoprotein physico-chemical properties
  - Title of qualification awarded Visiting Scientist
  - Level in national classification

## LANGUAGES

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

ENGLISH

Excellent

very good

Excellent

- Reading skills
- Writing skills
- Verbal skills

FRENCH

good

poor

good

## ADDITIONAL INFORMATION

## **Awards and Honors**

- 1993 American Heart Association: Corresponding Fellow
- 1996 American Federation for Clinical Research and Western Society for Clinical Investigation: Award for outstanding postdoctoral research
- 1996 Selection for presentation at the Chairman's Session at the Joint Plenary Session of WSCI, WSAFCR, Carmel, CA, 02/15/1996
- 1996 American Heart Association: 1996-97 Fellowship Award
- 1997 American Society for Clinical Investigation: Award for the best abstract presented at the Annual Meeting of the American Federation for Medical Research - Western Section.
- 1997 Young Faculty Award of the Western Society for Clinical Investigation
- 1998 American Federation For Aging Research (AFAR): 1998-2001 Paul Beeson Physician Faculty Scholar
- 1999 Merck Young Investigators Conference on Lipid Research: Award for outstanding research contribution
- 2000 Young Investigator Award – American Federation for Medical Research.
- 2000 Dorothy Dillon Eweson Lecture on the Advances in Aging Research by AFAR
- 2000 Award for Outstanding Scientific Contributions in Medical Research – Scientific Committee, School of Medicine, University of Padua, Italy
- 2001 Award for Outstanding Scientific Contributions in Medical Research – Scientific Committee, School of Medicine, University of Padua, Italy
- 2002 AZTECC International Award for Training and Education for Cardiovascular Clinicians

## **Scientific Societies and Advisory Board Membership**

- 1993- present Fellow and Silver Heart Member of the American Heart Association, Council on Arteriosclerosis, Thrombosis and Vascular Biology
- 1998- present Member of the Italian Society for the Study of Atherosclerosis (S.I.S.A.).
- 1998- present Member of the International Atherosclerosis Society (I.A.S.).
- 2003- present Member of the International Advisory Board of the Meeting on "Drugs Affecting Lipid Metabolism", DALM, Giovanni Lorenzini Foundation
- 2005- present Member of the Speakers Bureau of the International Atherosclerosis Society
- 2009 Member of the International Advisory Board – XV International Symposium on Atherosclerosis – Boston 14-18 June 2009
- 2011 Member of the International Advisory Board – XVI International Symposium on Atherosclerosis – Sydney 25-29 March 2012
- 2011- present Member of the European Atherosclerosis Society (E.A.S.)
- 2016 -present Chair of the International Atherosclerosis Society (IAS) Regional Federation of Europe
- 2016 -present Member of the Executive Board of the International Atherosclerosis Society

## Current Research Interests

Dr. Zambon is currently the Director of the lipoprotein core laboratory of the Centre for Atherosclerosis Prevention and Treatment of the Department of Medicine, University of Padua, Italy.

His current research projects focus on:

1. Mechanisms of atherosclerotic plaque progression and regression and particularly on the genetic background leading to lipoprotein abnormalities responsible for the unstable atherosclerotic plaque;
2. A second line of research focuses the common pathophysiological links between lipoprotein abnormalities, specifically related to particle size and density, and endothelial dysfunction both as an early marker of atherosclerosis as well as a potential link between the atherosclerotic process and venous thromboembolism;
3. A third line of research deals with lipid oxidation and brain small vessel disease (endothelial dysfunction at cerebral site) as potential clinically relevant background for the development of Alzheimer's Disease and predictor of cognitive decline.

## PUBLICATIONS

1. MANZATO E, ZAMBON S, ZAMBON A, CORTELLA A, CREPALDI G (1990).  
**Serum lipoprotein and apoprotein levels during ketanserine or metoprolol administration in hypertensive patients**  
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (47): 807-313  
[ISSN 0011-393X] PMID: **IF 0,333**.
2. MANZATO E, ZAMBON S, ZAMBON A, DIGITO M, CARRARO R, CREPALDI G, ENZI G (1992).  
**Lipoprotein sub-fraction levels and composition in obese subjects before and after gastroplasty.**  
INTERNATIONAL JOURNAL OF OBESITY (16): 573-8  
[ISSN 0307-0565] PMID: 1326487 **IF 3,640**
3. ZAMBON S, ZAMBON A, STABELLINI N, TARRONI G, GILLI P, CREPALDI G, MANZATO E (1993).  
**Lipoprotein abnormalities in hypertriglyceridaemic patients on long-term haemodialysis.**  
JOURNAL OF INTERNAL MEDICINE (234): 217-21  
[ISSN 0954-6820] PMID: 8340745 **IF 5,412**
4. ZAMBON A, HASHIMOTO SI, BRUNZELL JD (1993).  
**Analysis of techniques to obtain plasma for measurement of levels of free fatty acids.**  
JOURNAL OF LIPID RESEARCH (34): 1021-8  
[ISSN 0022-2275] PMID: 8354949 **IF 4,409**.
5. ZAMBON A, TORRES A, BIJVOET S, GAGNE C, MOORJANI S, LUPIEN PJ, HAYDEN MR, BRUNZELL JD (1993).  
**Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency.**  
LANCET (341): 1119-21  
[ISSN 0140-6736] PMID: 8097805 **IF 28,409**.
6. ZAMBON A, AUSTIN MA, BROWN BG, HOKANSON JE, BRUNZELL JD (1993).  
**Effect of hepatic lipase on LDL in normal males and those with coronary artery disease.**  
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (13):147-53  
[ISSN 1079-5642] PMID: 8427851 **IF 7,582**.
7. HOKANSON JE, AUSTIN MA, ZAMBON A, BRUNZELL JD (1993).  
**Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.**  
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (13): 427-34  
[ISSN 1079-5642] PMID: 8443147 **IF 7,582**.
8. MANZATO E, ZAMBON S, ZAMBON A, CORTELLA A, SARTORE G, CREPALDI G (1993).  
**Levels and physicochemical properties of lipoprotein subclasses in moderate hypertriglyceridemia..**  
CLIN CHIM ACTA (19):57-65  
[ISSN 0009-8981 ] PMID: 8306464 **IF 2,535**.

## PUBLICATIONS

9. MANZATO E, ZAMBON A, LAPOLLA A, ZAMBON S, BRAGHETTO L, CREPALDI G, FEDELE D (1993).  
**Lipoprotein abnormalities in well-treated type II diabetic patients.**  
DIABETES CARE (16): 469-75  
[ISSN 0149-5992] PMID: 8432219 **IF 7,349**.
10. CAPELL WH, ZAMBON A, AUSTIN MA, BRUNZELL JD, HOKANSON JE (1996)  
**Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B.**  
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (16):1040-6  
[ISSN 1079-5542] PMID: 8696944 **IF 7,582**.
11. NEVIN DN, ZAMBON A, FURLONG CE, RICHTER RJ, HUMBERT R, HOKANSON JE, BRUNZELL JD.(1996)  
**Paraoxonase genotypes, lipoprotein lipase activity, and HDL**  
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (16):1243-9  
[ISSN 1079-5542] PMID: 8857920 **IF 7,582**.
12. ZAMBON A, SCHMIDT I, BEISIEGEL U, BRUNZELL JD (1997).  
**Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins.**  
JOURNAL OF LIPID RESEARCH (37): 2394-404  
[ISSN 0022-2275] PMID: 8978491 **IF 4,409**.
13. ZAMBON A, DEEB SS, HOKANSON JE, BROWN BG, BRUNZELL JD (1998).  
**Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol.**  
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (18): 1723-9  
[ISSN 1079-5642] PMID: 9812910 **IF 7,582**.
14. ZAMBON A, HOKANSON JE (1998).  
**Lipoprotein classes and coronary disease regression.**  
CURRENT OPINION IN LIPIDOLOGY (9): 329-36  
[ISSN 0957-9672] PMID: 9739489 **IF 6,629**
15. BROWN BG, ZAMBON A, POULIN D, ROCHA A, MAHER VM, DAVIS JW, ALBERS JJ, BRUNZELL JD (1998).  
**Use of niacin, statins, and resins in patients with combined hyperlipidemia.**  
AMERICAN JOURNAL OF CARDIOLOGY (81): 52B-59B  
[ISSN 0002-9149] PMID: 9526815 **IF 3,905**.
16. ZAMBON A, SARTORE G, PASSERA D, FRANCINI-PESENTI F, BASSI A, BASSO C, ZAMBON S, MANZATO E, CREPALDI G (1999).  
**Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in mildly obese women.**  
JOURNAL OF INTERNAL MEDICINE (246): 191-201  
[ISSN 0954-6820] PMID: 10447788 **IF 5,412**
17. ZAMBON A, HOKANSON JE, BROWN BG, BRUNZELL JD (1999).  
**Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.**  
CIRCULATION (99): 1959-64  
[ISSN 0009-7322] PMID: 10208998 **IF 14,595**

## PUBLICATIONS

18. CARR MC, KIM KH, ZAMBON A, MITCHELL ES, WOODS NF, CASAZZA CP, PURNELL JQ, HOKANSON JE, BRUNZELL JD, SCHWARTZ RS (2000).  
**Changes in LDL density across the menopausal transition.**  
JOURNAL OF INVESTIGATIVE MEDICINE (48): 245-50  
[ISSN 1081-5589] PMID: 10916282 **IF 1,723.**
19. CORRAO G, RUBBIATI L, BAGNARDI V, ZAMBON A, POIKOLAINEN K (2000).  
**Alcohol and coronary heart disease: a meta-analysis.**  
ADDICTION (95): 1505-23  
[ISSN 0965-2140 ] PMID: 11070527 **IF 4.244.**
20. PURNELL JQ, ZAMBON A, KNOPP RH, PIZZUTI DJ, ACHARI R, LEONARD JM, LOCKE C, BRUNZELL JD (2000).  
**Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.**  
AIDS (14): 51-7  
[ISSN 0269-9370] PMID: 10714567 **IF 5,460.**
21. ZAMBON A, DEEB SS, BROWN BG, HOKANSON JE, BRUNZELL JD (2001).  
**Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.**  
CIRCULATION (103): 792-8  
[ISSN 0009-7322] PMID: 11171785 **IF 14,595.**
22. CARR MC, HOKANSON JE, ZAMBON A, DEEB SS, BARRETT PH, PURNELL JQ, BRUNZELL JD (2001).  
**The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity.**  
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM (86): 2831-7  
[ISSN 0021-972X] PMID: 11397895 **IF 6,325.**
23. ZAMBON A, BROWN BG, DEEB SS, BRUNZELL JD (2001).  
**Hepatic lipase as a focal point for the development and treatment of coronary artery disease.**  
JOURNAL OF INVESTIGATIVE MEDICINE (49): 112-8  
[ISSN 1081-5589] PMID: 11217140 **IF 1,723.**
24. ZAMBON A, DEEB SS, BENSADOUN A, FOSTER KE, BRUNZELL JD (2001).  
**In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity.**  
JOURNAL OF LIPID RESEARCH (41): 2094-9  
[ISSN 0022-2275] PMID: 11108744 **IF 4,409**
25. FAGGIN E, ZAMBON A, PUATO M, DEEB SS, BERTOCCO S, SARTORE S, CREPALDI G, PESSINA AC, PAULETTO P (2002).  
**Association between the --514 C-->T polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis.**  
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (40): 1059-66  
[ISSN 0735-1097] PMID: 12354428 **IF 11,438**

## PUBLICATIONS

26. RATAZZI M, PUATO M, FAGGIN E, BERTIPAGLIA B, ZAMBON A, PAULETTO P (2003).  
**C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?**  
JOURNAL OF HYPERTENSION (21): 1787-803  
[ISSN 0263-6352] PMID: 14508181 **IF 5,132**.
27. ZAMBON A, BERTOCCO S, VITTURI N, POLENTARUTTI V, VIANELLO D, CREPALDI G (2003).  
**Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.**  
BIOCHEMICAL SOCIETY TRANSACTIONS (31): 1070-4  
[ISSN 0300-5127] PMID: 14505482 **IF 2,979**
28. ZAMBON A, DEEB SS, PAULETTO P, CREPALDI G, BRUNZELL JD (2003).  
**Hepatic lipase: a marker for cardiovascular disease risk and response to therapy.**  
CURRENT OPINION IN LIPIDOLOGY (14): 179-89  
[ISSN 0957-9672] PMID: 12642787 **IF 6,629**
29. DEEB SS, ZAMBON A, CARR MC, AYYOBI AF, BRUNZELL JD (2003).  
**Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet.**  
JOURNAL OF LIPID RESEARCH (44): 1279-86  
[ISSN 0022-2275] PMID: 12639974 **IF 4,409**
30. ZAMBON A, PAULETTO P, CREPALDI G (2005).  
**Review article: the metabolic syndrome--a chronic cardiovascular inflammatory condition.**  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (22 Suppl 2): 20-23  
[ISSN 0269-2813] PMID: 16225466 **IF 3,710**
31. ZAMBON A, PUATO M, FAGGIN E, BERTOCCO S, VITTURI N, POLENTARUTTI V, DERIU GP, GREGO F, BERTIPAGLIA B, RATAZZI M, VIANELLO D, DEEB SS, PAULETTO P (2006).  
**Common hepatic lipase gene promoter variant predicts the degree of neointima formation after carotid endarterectomy: Impact of plaque composition and lipoprotein phenotype.**  
ATHEROSCLEROSIS (185): 121-6  
[ISSN 0021-9150] PMID: 16005462 **IF 4,601**.
32. ZAMBON A, GERVOIS P, PAULETTO P, FRUCHART JC, STAELS B (2006).  
**Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR- $\alpha$  Activators. Clinical and Experimental Evidence.**  
ARTERIOSCLER THROMB VASC BIOL 26(5):977-86  
[ISSN 1079-5642] PMID: 16424352 **IF 7,582**
33. ZAMBON A, BROWN BG, HOKANSON JE, MOTULSKY AG, BRUNZELL JD (2006).  
**Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.**  
JOURNAL OF INTERNAL MEDICINE (259): 401-9  
[ISSN 0954-6820] PMID: 16594908 **IF 5,412**.
34. ZAMBON A, BROWN BG, DEEB SS, BRUNZELL JD (2006).  
**Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.**  
JOURNAL OF INTERNAL MEDICINE (259): 473-80  
[ISSN 0954-6820 ] PMID: 16629853 **IF 5,412**

## PUBLICATIONS

35. ZAMBON A, (2006).  
**Reducing cardiovascular risk in the diabetic patient: implications from the FIELD study.**  
DIABETES VASC DIS. RES. (3, SUPPL. 1): S16-S20. PMID: 17935056 **IF 2,468**
36. CAGNING AC, ZAMBON A, ZARANTONELLO G, VIANELLO D, MARCHIORI M, MERCURIO D, BATTISTIN L (2007).  
**Serum lipoprotein phenotype and apo E genotype in Alzheimer's disease.**  
JOURNAL OF NEURAL TRANSMISSION 72:175-79,  
[ISSN 0300-9564 ] **IF 2,514**
37. MAGGI S, ZAMBON A, NOALE M, GALLINA P, BIANCHI D, MARZARI C, LIMONGI F, CREPALDI G for the ILSA Working Group (2007).  
**Validity of the ATP III diagnostic criteria for the Metabolic Syndrome in an elderly Caucasian population. The Italian Longitudinal Study on Aging.**  
ATHEROSCLEROSIS 197(2):877-82  
[ISSN 0021-9150 ] PMID: 16629853 **IF 4,601**
38. ZAMBON A, (2007).  
**Type 2 diabetes patients: profiles, treatment and daily practice.**  
DIABETES VASC DIS. RES. (4, SUPPL. 2): S12-S16  
PMID: 17935056 **IF 2,468**
39. ZAMBON A, CUSI K. (2007)  
**The role of fenofibrate in clinical practice.**  
DIABETES VASC DIS. RES. (4 SUPPL 3):S15-20.  
PMID: 17935056 **IF 2,468**
40. ZAMBON A, MARCHIORI M, MANZATO E. (2008)  
**Obesità viscerale e dislipidemia: meccanismi fisiopatologici, implicazioni cliniche e terapia.**  
G ITAL CARDIOL, 9 (SUPPL 1-4):S29-S39. [ISSN 1827-8981]
41. STAELS B, MAES M, ZAMBON A (2008)  
**Fibrates and future PPAR-alpha agonists in the treatment of cardiovascular disease.**  
NAT CLIN PRACT CARDIOVASC MED 5(9):542-53  
PMID: 18628776 **IF 5,972**
42. POLI A, MARANGONI F, PAOLETTI R, MANNARINO E, LUPATTELLI G, NOTARBARTOLO A, AURELI P, BERNINI F, CICERO A, GADDI A, CATAPANO A, CRICELLI C, MARROCCO W, PORRINI M, STELLA R, VANOTTI A, VOLPE M, VOLPE R, CANNELLA C, PINTO A, DEL TOMA E, LA VECCHIA C, TAVANI A, MANZATO E, RICCARDI G, SIRTORI C, ZAMBON A; *Nutrition Foundation Of Italy.* (2008)  
**Non-pharmacological control of plasma cholesterol levels.**  
NUTR METAB CARDIOVASC DIS 2008 Feb;18(2):S1-16.  
PMID: 18258418 **IF 3,438**

## PUBLICATIONS

43. FRUCHART J-C, SACKS F, HERMANS MP, ASSMANN G, BROWN WV, CHAPMAN MJ, DODSON PM, FIORETTO P, GINSBERG HN, KADOWAKI T, LABLANCHE J-M, MARX N, PLUTZKY J, ROSENSON RS, SMITH Jr SC, STAELS B, STOCK JK, SY R, WANNER C, ZAMBON A, ZIMMET P (2008)  
**The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia**  
DIABETES VASC DIS. RES. 5(4):319-335. PMID: 17935056 **IF 2,468**
44. FRUCHART J-C, SACKS F, HERMANS MP, ASSMANN G, BROWN WV, CHAPMAN MJ, DODSON PM, FIORETTO P, GINSBERG HN, KADOWAKI T, LABLANCHE J-M, MARX N, PLUTZKY J, ROSENSON RS, SMITH Jr SC, STAELS B, STOCK JK, SY R, WANNER C, ZAMBON A, ZIMMET P (2008)  
**The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia**  
AM J CARDIOL. 17;102(10 SUPPL):1K-34K. **IF 3,905**
45. NORATA GD, RASELLI S, GRIGORE L , MAGGI FM, GARLASCHELLI K, VIANELLO D, BERTOCCO S, ZAMBON A, CATAPANO AL (2009)  
**Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells**  
ATHEROSCLEROSIS, 206(2):556-62. **IF 4,086**
46. WINNICKI M, PUATO M, SOMERS VK, ZAMBON A, MARCOVINA SM, RATTAZZI M, PHILLIPS BG, PAULETTO P (2010)  
**Leptin is Associated with the Size of the Apolipoprotein(a) Particle in African Tribal Populations Living on Fish or Vegetarian Diet.**  
ATHEROSCLEROSIS, 211(1):303-7 **IF 4,086**
47. PUATO M, FAGGIN E, RATTAZZI M, ZAMBON A, CIPOLLONE F, GRAGO F, GANASSIN L, PLEBANI M, MEZZETTI A, PAULETTO P. (2010) **Atorvastatin Reduces Macrophage Accumulation in Atherosclerotic Plaques: A Comparison of a Nonstatin-Based Regimen in Patients Undergoing Carotid Endarterectomy.**  
STROKE, 41(6):1163-68 **IF 5,756**
48. FRUCHART JC, SACKS FM, HERMANS MP, et al. (2010)  
**Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R<sup>3</sup>i).**  
CURR MED RES OPIN, 26(8):1793-97 **IF 2,498**
49. MAFFEIS C, PINELLI L, SURANO MG, FORNARI E, CORDIOLI S, VIANELLO D, CORRADI M, ZAMBON A (2012)  
**Pro-atherogenic postprandial profile: meal induced changes of lipoprotein sub-fractions and inflammation markers in obese boys.**  
NUTR METAB CARDIOVASC DIS. Mar 18. [Epub ahead of print] **IF 3,438**
50. CAGNIN A, POMPANIN S, MANFIOLI V, BRIANI C, ZAMBON A, SALADINI M, DAM M. (2011)  
**Gamma-hydroxybutyric acid - induced psychosis and seizures.**  
EPILEPSY & BEHAVIOR, 21:203-205. **IF 1,994**
51. BRUNZELL JD, ZAMBON A, DEEB SS (2012)  
**The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype**  
BBA - Molecular and Cell Biology of Lipids, doi:10.1016/j.bbalip.2011.09.008 **IF 5,084**

## PUBLICATIONS

52. MIKHAILIDIS DP, ELISAF MS, RIZZO M, BERNEIS K, GRIFFIN B, ZAMBON A, ATHYROS V, DE GRAAF J, MÄRZ W, PARHOFER KG, RINI GB, SPINAS GA, TOMKIN GH, TSELEPIS AD, WIERZBICKI AS, WINKLER K, FLORENTIN M, POULOS EN (2011)  
**"European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses**  
CURR VASC PHARMACOL, 9:533-571. **IF 2,896**
53. MIKHAILIDIS DP, ELISAF MS, RIZZO M, BERNEIS K, GRIFFIN B, ZAMBON A, ATHYROS V, DE GRAAF J, MÄRZ W, PARHOFER KG, RINI GB, SPINAS GA, TOMKIN GH, TSELEPIS AD, WIERZBICKI AS, WINKLER K, FLORENTIN M, POULOS EN (2011)  
**"European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary.**  
CURR VASC PHARMACOL, 9:531-532. **IF 2,896**
54. ZAMBON A. (2011)  
**Residual cardiovascular risk in secondary prevention**  
INTERN EMERG MED Oct 6, suppl. 1: 61-68 PMID: 22009614 **IF 2,139**
55. PUATO M, ZAMBON A, FAGGIN E, RATTAZZI M, PAULETTO P. (2014)  
**Statin treatment and carotid plaque composition. Review of clinical studies**  
CURR VASC PHARMACOL E-PUB Oct 17 PMID: 23092412 **IF 2,896**
56. CAGNIN A, LEON A, VIANELLO D, COLAVITO D, FAVARETTO S, ZARANTONELLO G, STECCA A, ERMANI M, ZAMBON A (2013)  
**LDL Density and oxidation are modulated by PON1 promoter genotype in patients with Alzheimer's disease**  
J ALZHEIMERS 34(2):377-385 PMID: 23207490 **IF 3,745**
57. TAGLIEPIETRA M, ZANUSSO G, FIORINI M, BONETTO N, ZARANTONELLO G, ZAMBON A, ERMANI M, MONACO S, MANARA R, CAGNIN A (2013)  
**Accuracy of diagnostic criteria for sporadic Creutzfeld-Jacob disease among rapidly progressive dementia**  
J ALZHEIMERS DIS 34(1): 231-238 PMID: 23207489 **IF 3,7451**
58. ZAMBON A, PUATO M, FAGGIN E, GREGO F, RATTAZZI M, PAULETTO P. (2013)  
**Lipoprotein remnants and dense LDL are associated with features of unstable atherosclerotic plaque: a Flag for non-HDL-C**  
ATHEROSCLEROSIS 230:106-109 **IF 4,086**
59. FRUCHART J-C, DAVIGNON J, HERMANS MP, AL-RUBEAN K, AMARENCO P, ASSMANN G, BARTER P, BETTERIDGE J, BRUKERT E, CUEVAS A, FARNIER M, FERRANINI E, FIORETTO P, GENEST J, GINSBERG HN, ZAMBON A ZHU J, ZIMMETH (2014)  
**Residual macrovascular risk in 2013: What have we learned?**  
CARDIOVASCULAR DIABETOLOGY Jan 24;13(1):26 **IF 4,209**
60. ZAMBON A, ZHAO X-Q, BROWN BG, BRUNZELL JD (2014)  
**Niacin combination therapy, lipoproteins and cardiovascular disease**  
AM J CARDIOLOGY May 1;113(9):1494-8. PMID: 24641964
61. ZAMBON A, (2015)  
**The new ACC/AHA guidelines on the treatment of dyslipidemia: cons.**  
INTERN EMERG ,ED 10(2): 119-122 PMID: 25502590

62. AGUIAR C, ALEGRIA E, BONADONNA RC, CATAPANO AL, COSENTINO F, ELISAF M, FARNIER M, FERRIÈRES J, FILARDI PP, HANCU N, KAYIKCIOGLU M, MELLO E SILVA A, MILLAN J, REINER Ž, TOKGOZOGLU L, VALENSI P, VIIGIMAA M, VRABLIK M, ZAMBON A, ZAMORANO JL, FERRARI R., (2015)  
**A review of the evidence of reducing macrovascular risk in patients with atherogenic dyslipidemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy**  
ATHEROSCLER SUPPL Sept 2015;19:1-12 doi: 10.1016/S1567-5688(15)30001-5. PMID:26315511
63. VITTURI N, SOATTIN M, De STEFANO F, VIANELLO D, ZAMBON A, PLEBANI M, BUSETTO L (2015)  
**Ultrasound, anthropometry and bioimpedance: a comparison in prediabetic fat deposition in non-alcoholic fatty liver disease.**  
EAT WEIGHT DISORD 20(2):241-247. PMID:25129033.
64. ARCA M, AVERNA M, CASULA M, CATAPANO AL, FELLIN R, ANGELICO F, AROSIO E, BERNINI F, CALANDRA S, CIPOLLONE F, CORSINI A, MEROTTA G, MUNTONI S, POLI A, SOLINI A, VAUDO G, ZAMBON A (2016)  
**Nuove terapie ipolipemizzanti per i pazienti con ipercolesterolemia familiare: Position paper della Società Italiana per lo studio della Arteriosclerosi**  
GIORNALE ITALIANO DELL'ARTERIOSCLEROSI 7(1):45-65.
65. FERRARI R, AGUIAR C, ALEGRIA E, BANADONNA RC, COSENTINO F, ELISAF M, FARNIER M, FERRIERES J, PERRONE FILARDI P, HANCU N, KAYIKCIOGLU M, MELLO E SILVA A, MILLAN J, REINER Z, TOKGOZOGLU L, VALENSI P, VIIGIMAA M, VRABLIK M, ZAMBON A, ZAMORANO JL, CATAPANO AL (2016)  
**Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidemia.**  
EUR HEART J SUPPL 18:2-12 The Heart of the Matter doi:10.1093/eurheartj/suw009
66. ZAMBON A (2016)  
**Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies.**  
G ITAL CARDIOL (Rome). Apr;17(4):22-30. doi:10.1714/2254.24280 PMID:27312020.
67. CIMMINIELLO C, ZAMBON A, POLO FRIZ H (2016)  
**Hypercholesterolemia and cardiovascular risk: advantages and limitations of current treatment options.**  
G ITAL CARDIOL (Rome). Apr;17(4)6-13. doi: 10.1714/2254.24276 PMID:27312018

1. MANZATO E, ZAMBON S, ZAMBON A., CREPALDI G. *Dietary and drug treatment of dyslipidemias*  
In: **ADVANCES IN VASCULAR PATHOLOGY** STRANO A, NOVO S.  
Elsevier Science Publishers B.V. (1989) Vol. , pp. 1389-1394.
2. ZAMBON A., BRUNZELL J.D. *THE LIPOPROTEIN METABOLISM IN THE PLURIMETABOLIC SYNDROME*  
In: **DIABETES, OBESITY AND HYPERLIPIDEMIA: THE PLURIMETABOLIC SYNDROME** CREPALDI G., TIENGO A., MANZATO E.  
ELSEVIER SCIENCE PUBLISHER B.V. (1993) Vol. 1039, pp. 197-200.
3. BRUNZELL J.D., AUSTIN M.A., DEEB S.S., HOKANSON J.E., JARVIK J.P., NEVIN D.N., WIJSMAN E., ZAMBON A., MOTULSKY A.G. *FAMILIAL COMBINED HYPERLIPIDEMIA AND GENETIC RISK FOR ATHEROSCLEROSIS*  
In: **ATHEROSCLEROSIS X** WOODFORD F.P., DAVIGNON J., SNIDERMAN A.  
ELSEVIER SCIENCE PUBLISHER B.V. (1995) Vol. , pp. 624-627.
4. ZAMBON A., BRUNZELL J.D *FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA*  
In: **HANDBUCH DER FETTSTOFFWECHSELSTORUNGEN** SCHWANDT P., RICHTER W.O., PARHOFER K.  
SCHATTAUER (2001) Vol. , pp. 104-114.
5. CREPALDI G., ZAMBON A. *La Sindrome Plurimetabolica: storia ed attualità*  
In: **4° Rapporto sull'Obesità in Italia** ISTITUTO AUXOLOGICO ITALIANO FRANCO ANGELI (2002) Vol. , pp. 5-28.
6. ZAMBON A., CREPALDI G *The Plurimetabolic Syndrome: qualitative lipoprotein abnormalities and atherosclerosis*  
In: **The metabolic Syndrome: diabetes , obesity, hyperlipidemiai and hypertension** CREPALDI G, TIENGO A, AVOGARO A.  
Elsevier (2003) Vol. 1253, pp. 223-228.
7. VITTURI N, ZAMBON A., POLENTARUTTI V, BERTOCCO S, VIANELLO D, PAULETTO P, CREPALDI G *Dyslipidemia of the Plurimetabolic Syndrome and risk of cerebrovascular events*  
In: **The metabolic Syndrome: diabetes, obesity, hyperlipidemia and hypertension** CREPALDI G, TIENGO A, AVOGARO A  
ELSEVIER (2003) Vol. 1253, pp. 209-215.
8. ZAMBON A *Insulino-resistenza e Dislipidemia*  
In: **INSULINO-RESISTENZA E SINDROME METABOLICA** Del Prato S  
Primula Editrice (2005) Vol. , pp. 20-36.
9. PARHOFER K., ZAMBON A., BRUNZELL J.D *FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA*  
In: **HANDBUCH DER FETTSTOFFWECHSELSTORUNGEN: dyslipoproteinämien und atherosklerose: diagnostik, terapie und prävention** (3rd Edition) SCHWANDT P., PARHOFER K.  
SCHATTAUER (2007) Vol. , pp. 146-155.

Padova June 28th, 2016



